Ren Yuan Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ren Yuan Lee has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Joe Yeong
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China
3 shared publications Jeffrey Chun Tatt Lim
Institute of Molecular and Cell Biology (IMCB) Agency for Science, Technology and Research (A*STAR) Singapore 138673 Singapore
2 shared publications- Tony Kiat Hon Lim
Department of Anatomical Pathology, Singapore General Hospital, 20 College Road, Singapore 169856, Singapore
2 shared publications Benedict Tan
Institute of Molecular Cell Biology (IMCB), Agency of Science, Technology and Research (A*STAR), Singapore
1 shared publicationBernett Lee
Singapore Immunology Network (SIgN), Agency of Science, Technology and Research (A*STAR), Singapore
1 shared publicationBijin Au
Institute of Molecular Cell Biology (IMCB), Agency of Science, Technology and Research (A*STAR), Singapore
1 shared publication
Latest Publications
- 30 January 2024
- Published by World Scientific Pub Co Pte Ltd in World Scientific Annual Review of Cancer Immunology
- Vol. 01
H&E2.0 — Harnessing Artificial Intelligence to Enhance Biomarker Prediction Using Hematoxylin and Eosin-Stained Image
Recent advances in clinical and research pathology are fueled by new histomorphological and molecular techniques, moving beyond traditional methods like Hematoxylin and Eosin (H&E) and immunohistochemical (IHC), which offer limited information and have high observer variability. Advanced methods like spatial omics provide detailed molecular mapping but are costly and complex. Artificial intelligence (AI) has emerged as a promising solution to these challenges by digitally predicting cellular and molecular biomarkers from H&E-stained images. This review highlights the development of a new field, H&E 2.0, which focuses on current and emerging AI advancements leveraging H&E stained images. We discuss the current capabilities of H&E 2.0 in predicting bulk biomarker quantity at the sample level, generating virtual staining at cellular resolution, and inferring in situ gene expression information from H&E slides across various tumor types. Additionally, we offer insights into the current challenges and potential future directions in this evolving field.
- 30 January 2024
- Published by World Scientific Pub Co Pte Ltd in World Scientific Annual Review of Cancer Immunology
- Vol. 01
H&E2.0 — Harnessing Artificial Intelligence to Enhance Biomarker Prediction Using Hematoxylin and Eosin-Stained Image
Recent advances in clinical and research pathology are fueled by new histomorphological and molecular techniques, moving beyond traditional methods like Hematoxylin and Eosin (H&E) and immunohistochemical (IHC), which offer limited information and have high observer variability. Advanced methods like spatial omics provide detailed molecular mapping but are costly and complex. Artificial intelligence (AI) has emerged as a promising solution to these challenges by digitally predicting cellular and molecular biomarkers from H&E-stained images. This review highlights the development of a new field, H&E 2.0, which focuses on current and emerging AI advancements leveraging H&E stained images. We discuss the current capabilities of H&E 2.0 in predicting bulk biomarker quantity at the sample level, generating virtual staining at cellular resolution, and inferring in situ gene expression information from H&E slides across various tumor types. Additionally, we offer insights into the current challenges and potential future directions in this evolving field.
- 26 April 2023
- Published by Wiley in Advanced Healthcare Materials
- Vol. 12 (14) , e2202457
Application of Artificial Intelligence to In Vitro Tumor Modeling and Characterization of the Tumor Microenvironment
In vitro tumor models have played vital roles in enhancing the understanding of the cellular and molecular composition of tumors, as well as their biochemical and biophysical characteristics. Advances in technology have enabled the evolution of tumor models from two‐dimensional cell cultures to three‐dimensional printed tumor models with increased levels of complexity and diverse output parameters. With the increase in complexity, the new generation of models is able to replicate the architecture and heterogeneity of the tumor microenvironment more realistically than their predecessors. In recent years, artificial intelligence (AI) has been used extensively in healthcare and research, and AI‐based tools have also been applied to the precise development of tumor models. The incorporation of AI facilitates the use of high‐throughput systems for real‐time monitoring of tumorigenesis and biophysical tumor properties, raising the possibility of using AI alongside tumor modeling for personalized medicine. Here, the integration of AI tools within tumor modeling is reviewed, including microfluidic devices and cancer‐on‐chip models.
- 26 April 2023
- Published by Wiley in Advanced Healthcare Materials
- Vol. 12 (14) , e2202457
Application of Artificial Intelligence to In Vitro Tumor Modeling and Characterization of the Tumor Microenvironment
In vitro tumor models have played vital roles in enhancing the understanding of the cellular and molecular composition of tumors, as well as their biochemical and biophysical characteristics. Advances in technology have enabled the evolution of tumor models from two‐dimensional cell cultures to three‐dimensional printed tumor models with increased levels of complexity and diverse output parameters. With the increase in complexity, the new generation of models is able to replicate the architecture and heterogeneity of the tumor microenvironment more realistically than their predecessors. In recent years, artificial intelligence (AI) has been used extensively in healthcare and research, and AI‐based tools have also been applied to the precise development of tumor models. The incorporation of AI facilitates the use of high‐throughput systems for real‐time monitoring of tumorigenesis and biophysical tumor properties, raising the possibility of using AI alongside tumor modeling for personalized medicine. Here, the integration of AI tools within tumor modeling is reviewed, including microfluidic devices and cancer‐on‐chip models.
- Open Access
- 26 August 2020
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (2) , e000987
Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
Introduction: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-associated mortality globally. Immune-checkpoint blockade (ICB) is one of the systemic therapy options for HCC. However, response rates remain low, necessitating robust predictive biomarkers. In the present study, we examined the expression of CD38, a molecule involved in the immunosuppressive adenosinergic pathway, on immune cells present in the tumor microenvironment. We then investigated the association between CD38 and ICB treatment outcomes in advanced HCC. Methods: Clinically annotated samples from 49 patients with advanced HCC treated with ICB were analyzed for CD38 expression using immunohistochemistry (IHC), multiplex immunohistochemistry/immunofluorescence (mIHC/IF) and multiplex cytokine analysis. Results: IHC and mIHC/IF analyses revealed that higher intratumoral CD38+ cell proportion was strongly associated with improved response to ICB. The overall response rates to ICB was significantly higher among patients with high proportion of total CD38+cells compared with patients with low proportion (43.5% vs 3.9%, p=0.019). Higher responses seen among patients with a high intratumoral CD38+cell proportion translated to a longer median progression-free survival (mPFS, 8.21 months vs 1.64 months, p=0.0065) and median overall survival (mOS, 19.06 months vs 9.59 months, p=0.0295). Patients with high CD38+CD68+macrophage density had a better mOS of 34.43 months compared with 9.66 months in patients with low CD38+CD68+ macrophage density. CD38hi macrophages produce more interferon γ (IFN-γ) and related cytokines, which may explain its predictive value when treated with ICB. Conclusions: A high proportion of CD38+ cells, determined by IHC, predicts response to ICB and is associated with superior mPFS and OS in advanced HCC.
- 26 August 2020
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (2) , e000987
Open AccessImmunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
Introduction: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-associated mortality globally. Immune-checkpoint blockade (ICB) is one of the systemic therapy options for HCC. However, response rates remain low, necessitating robust predictive biomarkers. In the present study, we examined the expression of CD38, a molecule involved in the immunosuppressive adenosinergic pathway, on immune cells present in the tumor microenvironment. We then investigated the association between CD38 and ICB treatment outcomes in advanced HCC. Methods: Clinically annotated samples from 49 patients with advanced HCC treated with ICB were analyzed for CD38 expression using immunohistochemistry (IHC), multiplex immunohistochemistry/immunofluorescence (mIHC/IF) and multiplex cytokine analysis. Results: IHC and mIHC/IF analyses revealed that higher intratumoral CD38+ cell proportion was strongly associated with improved response to ICB. The overall response rates to ICB was significantly higher among patients with high proportion of total CD38+cells compared with patients with low proportion (43.5% vs 3.9%, p=0.019). Higher responses seen among patients with a high intratumoral CD38+cell proportion translated to a longer median progression-free survival (mPFS, 8.21 months vs 1.64 months, p=0.0065) and median overall survival (mOS, 19.06 months vs 9.59 months, p=0.0295). Patients with high CD38+CD68+macrophage density had a better mOS of 34.43 months compared with 9.66 months in patients with low CD38+CD68+ macrophage density. CD38hi macrophages produce more interferon γ (IFN-γ) and related cytokines, which may explain its predictive value when treated with ICB. Conclusions: A high proportion of CD38+ cells, determined by IHC, predicts response to ICB and is associated with superior mPFS and OS in advanced HCC.